Neopharm
Neopharm officials describe recent developments
Published in Healthcare Mergers, Acquisitions and Ventures Week, March 17th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Neopharm.
Report 1: Neopharm, Inc. (NEOL) announced that the pivotal Phase III PRECISE trial evaluating cintredekin besudotox (IL13-PE38QQR) for the treatment of recurrent glioblastoma multiforme did not meet the efficacy endpoint at 215 deaths, which was a statistically significant difference, or separation, in the overall survival curves versus Gliadel Wafer.
"Topline data suggests that cintredekin besudotox, while comparable, was not statistically superior to Gliadel," said...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
More Articles from Healthcare Mergers, Acquisitions and Ventures Week
- Accenture
Consumers See Electronic Health Records as Important Factor when Choosing a Physician and Are Willing to Pay for the Service, Accenture Research Finds - Actavis U.S.
Actavis Launches Hydrochlorothiazide 12.5 mg Tablets in the U.S. - ActivIdentity Corporation
ActivIdentity Expands Solutions Suite for Health Care with Introduction of SecureLogin Kiosk - Acumentra Health
Oregon Statewide IHI Campaign Expands to Protect 5 Million Lives From Harm - Addiction Medicine
Cambridge Who's Who Honors Cindy Warren's Marriage, Family and Substance Abuse Counseling - Adverse Drug Reactions
Research conducted at Pfizer Inc. has provided new information about adverse drug reactions - More from this issue of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
